ANTX compared with SABS: revenue, margins and what each company keeps, and the suppliers and customers both name

ANTXAN2 Therapeutics, Inc.

Mkt capRevenueRevenue

SABSSAB Biotherapeutics, Inc.

Mkt capRevenueRevenue

Compare

ANTXAN2 Therapeutics, Inc.

SABSSAB Biotherapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

ANTXAN2 Therapeutics, Inc.

4.18▼−3.98%· post 4.18· delayed

Mkt cap$164.2MRevenue—

SABSSAB Biotherapeutics, Inc.

3.12▼−5.52%· post 3.12· delayed

After hoursNov 3 '26delayed

Mkt cap$300.3MRevenue$114,698Q4 FY24

Compare

After hoursNov 3 '26delayed

ANTXAN2 Therapeutics, Inc.

SABSSAB Biotherapeutics, Inc.

4.18▼−3.98%post 4.18delayed

Price

3.12▼−5.52%post 3.12delayed

$164.2M

Mkt cap

$300.3M

—

Revenue

$114,698Q4 FY24

ANTX4.18▼−3.98%vsSABS3.12▼−5.52%After hoursNov 3 '26delayed

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

ANTX: latest quarter not drawable. SABS: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only ANTX 0

None

Shared 0

No disclosed counterparties: ANTX.

Only SABS 5

EBSEmergent BioSolutions Canadasupplier

—Avance Clinical PTY, Ltd ("Avance")unlistedsupplier

—Fortrea Holdings Inc. ("Fortrea")unlistedsupplier

—Sanford Applied Biosciencesunlistedsupplier

1 more · SABS chain ›

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Price

rebased to 0%

ANTX, solidSABS, dashed